10-K: Context Therapeutics Advances Cancer Pipeline, Reports Increased Losses

Context Therapeutics Inc. reported a net loss of $36.1 million for 2025 as it advanced its bispecific antibody pipeline for solid tumors, with key clinical trial data expected in 2026.

Summary

• Context Therapeutics is a clinical-stage biopharmaceutical company focused on T cell engaging (TCE) bispecific antibodies for solid tumors.
• The company's pipeline includes CTIM-76 (CLDN6 x CD3 TCE), CT-95 (MSLN x CD3 TCE), and CT-202 (Nectin-4 x CD3 TCE).
• CTIM-76's Phase 1 trial dosed its first patient in January 2025, with interim Phase 1a data expected in June 2026.
• CT-95's Phase 1 trial dosed its first patient in April 2025, with interim Phase 1a data expected in September 2026.
• CT-202 is expected to dose its first patient in a Phase 1 trial in Australia in the third quarter of 2026, following HREC application submission in March 2026.
• The company reported a net loss of $36.1 million for the year ended December 31, 2025, an increase from $26.7 million in 2024.
• Research and development expenses increased by 40% to $31.9 million in 2025, driven by clinical trial progression and milestone payments.
• As of December 31, 2025, cash and cash equivalents were $66.0 million, projected to fund operations into mid-2027.
• A stockholder class action challenging certain corporate governance provisions was resolved via a stipulated judgment on March 11, 2026, leading to changes in director election and removal rules.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative filing. While the company is making progress in advancing its pipeline into clinical trials and has sufficient cash for the near term, the significant increase in net loss and cash burn, coupled with the early stage of all product candidates and the need for substantial future funding, indicates ongoing financial challenges and high execution risk inherent in biopharmaceutical development.

Positives

• Progression of CTIM-76 into Phase 1 clinical trial with first patient dosed in January 2025.
• Progression of CT-95 into Phase 1 clinical trial with first patient dosed in April 2025.
• Advancement of CT-202 towards first-in-human trial initiation in Q3 2026.
• Anticipated interim Phase 1a data for CTIM-76 in June 2026 and for CT-95 in September 2026, providing potential early insights into efficacy and safety.
• Successful capital raises in 2024, including a $100 million private placement and an at-the-market offering, providing liquidity.
• Cash and cash equivalents of $66.0 million as of December 31, 2025, expected to fund operations into mid-2027.
• Resolution of a stockholder class action lawsuit regarding corporate governance, clarifying director election and removal processes.

Negatives

• Increased net loss of $36.1 million in 2025, up 35% from $26.7 million in 2024.
• Accumulated deficit grew to $130.9 million as of December 31, 2025.
• Significant increase in research and development expenses by 40% to $31.9 million in 2025.
• Cash and cash equivalents decreased from $94.4 million in 2024 to $66.0 million in 2025.
• The company has never been profitable and expects to incur significant expenses and operating losses for the foreseeable future.
• Reliance on third parties for manufacturing and clinical trials introduces risks of delays or failures.
• Awareness of third-party patents potentially covering CTIM-76, which could lead to infringement claims or require costly licensing.

Risks

• Never achieved profitability and may never achieve or maintain profitability.
• Need to raise additional funding, which may not be available on acceptable terms or at all, potentially forcing delays or termination of product development.
• Inability to successfully integrate recent and future acquisitions (e.g., CT-95).
• Limited operating history makes it difficult to evaluate current business and future prospects.
• Risk of expending limited resources on less successful or profitable research programs or product candidates.
• Fluctuating foreign exchange rates could increase operating expenses.
• Inflation, geopolitical developments, global supply chain disruptions, and public health concerns could adversely affect business.
• Changes in U.S. trade policy, including tariffs, may have a material adverse impact.
• Business is dependent on the successful development, regulatory approval, and commercialization of CTIM-76, CT-95, and CT-202, which are in early stages.
• Results of preclinical studies, early clinical trials, or analyses may not be indicative of results obtained in later trials.
• Interim top-line and preliminary data from clinical trials may change as more patient data becomes available.
• Any product candidate may cause serious adverse events or undesirable side effects, potentially delaying or preventing marketing approval.
• Difficulties in enrolling patients in clinical trials could delay clinical development.
• Success depends on the ability to identify, develop, and commercialize products using proprietary technologies.
• Reliance on a central team of limited employees and consultants presents operational challenges.
• Future success depends on retaining executive officers and key personnel and attracting qualified personnel.
• Dependence on collaborations with third parties for research, development, and commercialization activities.
• Inability to obtain sufficient quantities of raw materials and supplies at acceptable prices and on a timely basis.
• Potential disagreements or disputes with licensees, licensors, and other counterparties.
• Lengthy and time-consuming FDA regulatory approval process, with potential for significant delays.
• CTIM-76, CT-95, and CT-202, as biologics, may be subject to competition from biosimilar applicants.
• FDA may disagree with regulatory plans, leading to failure to obtain regulatory approval.
• Obtaining regulatory approval in one jurisdiction does not guarantee success in others.
• Even if approved, products may not gain market acceptance.
• Coverage and reimbursement may be limited or unavailable, making profitable sales difficult.
• Patents and patent applications involve complex legal and factual questions, which could negatively impact business.
• Third parties may assert infringement claims, or the company may need to defend/enforce patents, leading to substantial costs or delays.
• Ability to compete effectively may decline without adequate protection of proprietary rights.
• Failure to comply with obligations in intellectual property license agreements could lead to loss of rights.
• Inability to protect intellectual property rights throughout the world.
• Common stock price may be volatile or decline regardless of operating performance.
• May not be able to maintain compliance with Nasdaq listing requirements (e.g., minimum bid price).
• Raising additional capital may cause dilution, restrict operations, or require relinquishing rights.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell common stock.
• Subject to less rigorous public reporting requirements as an emerging growth company.
• Failure to maintain effective internal control over financial reporting and disclosure controls.
• Increased costs as a public company.
• Subject to complex tax rules, with potential for audits or investigations.
• Business and operations would suffer in the event of system failures or security breaches.
• Adverse developments affecting the financial services industry could affect operations.
• Adversely affected by natural or manmade disasters.
• Subject to claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties or former employers.
• Could be subject to securities class action litigation or litigation challenging corporate governance provisions.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its product candidates through development and clinical trials, and ultimately seeks regulatory approval. Cash and cash equivalents are projected to fund operations into mid-2027, but substantial additional funding will be required to support ongoing operations and growth strategy. Key milestones include sharing Phase 1a interim data for CTIM-76 in June 2026 and for CT-95 in September 2026, and dosing the first patient in the CT-202 Phase 1 trial in the third quarter of 2026.

Management Comments

• Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, CT-95 and CT-202.
• We believe our team and capabilities position us to be a leader in developing novel therapies targeting solid tumors.
• Our goal is to deliver safe and effective selective cancer therapies for patient populations with significant unmet medical needs.
• We believe CTIM-76 has the potential to be a differentiated CLDN6 product candidate, due in part to: (i) its high selectivity for CLDN6 over Claudin 3 (CLDN3), Claudin 4 (CLDN4), and Claudin 9 (CLDN9); and (ii) its potential ability to target tumors with low, medium or high levels of CLDN6 expression, which could potentially result in a broader target population and greater commercial opportunity compared with other approaches.
• We believe CT-95 has the potential to be a differentiated MSLN product candidate, due in part to: (i) its ability to bind to the membrane-proximal side of MSLN, which has been shown to increase potency compared to a historic program from Harpoon Therapeutics (HPN536), potentially driving improved outcomes for patients; (ii) avidity enhancement that aims to minimize the risk of adverse events, including cytokine release syndrome and hypoxia; and (iii) its potential ability to target tumors with low, medium or high levels of MSLN expression, which could potentially result in a broader target population and greater commercial opportunity compared with non-TCE approaches.
• We believe CT-202 has the potential to be a differentiated Nectin-4 product candidate, due in part to: (i) its ability to preferentially bind to Nectin-4 and CD3 in the low pH environment of tumor relative to pH neutral normal tissue, which has the potential to reduce the risk of dermatologic side effects associated with Nectin-4 expression in the skin; (ii) avidity enhancement to improve CT-202 residence in the tumor microenvironment and minimize the risk of cytokine release syndrome; and (iii) its potential ability to target tumors with low, medium or high levels of Nectin-4 expression, which could potentially result in a broader target population and greater commercial opportunity compared with non-TCE approaches.
• We believe that this strategy [relying on third-party manufacturers] allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our current and any future product candidates.
• We believe that our employee relations are good.
• Our talented employees are focused on driving our business with the foundation for all our efforts being to advance medicines for solid tumors.
• Our goal is that each colleague feels a deep connection to what they do, loves coming to work, and is aligned to our mission.
• Our management team works closely with our Information Technology provider to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.
• Our SVP of Operations is continually informed about the latest developments in cybersecurity, including potential threats and innovative risk management techniques.

Industry Context

StockSavvy.ai notes that Context Therapeutics operates in the highly competitive and rapidly advancing field of oncology, specifically targeting solid tumors with T cell engaging bispecific antibodies. The company's strategy to target clinically validated proteins like CLDN6, MSLN, and Nectin-4 with differentiated TCE approaches aligns with broader industry trends seeking more precise and effective cancer therapies. However, the early stage of its pipeline (Phase 1 trials) places it behind more established players with later-stage assets or approved products, such as BioNTech, TORL, Daiichi Sankyo (CLDN6), Amgen, RemeGen Biosciences (MSLN), and Pfizer, Bicycle Therapeutics, Eli Lilly (Nectin-4). The focus on broader patient populations (low, medium, high expression) and reduced side effects (pH-dependence for CT-202) represents an attempt to carve out a competitive advantage in crowded therapeutic areas.

Comparison to Industry Standards

• Context Therapeutics' CTIM-76 aims to target CLDN6, a target also pursued by BioNTech (BNT211), TORL (TORL-1-23), and Daiichi Sankyo (DS9606a). While these competitors use ADC and CAR T-cell approaches, CTIM-76's TCE approach is designed to target a broader patient population with varying CLDN6 expression levels, potentially differentiating it from competitors that require high expression.
• For MSLN, Context's CT-95 competes with candidates like Amgen's AMG-305 (TCE), RemeGen Biosciences' RC88 (ADC), and TCR2 Therapeutics' gavocabtagene autoleucel (CAR T-cell). CT-95's design to overcome shed MSLN (sMSLN) and bind to membrane-proximal MSLN epitope with high avidity aims to improve potency and therapeutic window compared to historical programs like Harpoon Therapeutics' HPN536.
• In the Nectin-4 space, CT-202 faces competition from Pfizer's approved ADC Padcev and Bicycle Therapeutics' BT8009 (ADC), as well as other TCE candidates like Bicycle Therapeutics' BT7480. CT-202's pH-dependent binding is a novel design intended to reduce dermatological side effects associated with Nectin-4 expression in healthy skin, a known issue with traditional Nectin-4 ADCs like Padcev.
• The company's early-stage clinical development (Phase 1) for all three lead candidates is standard for a biopharmaceutical company of its size, but it means significant capital and time are still required to reach market.

Management Changes

Corporate Governance

Legal Proceedings

• On February 4, 2026, the Vladimir Gusinsky Revocable Trust filed a stockholder class action complaint against the company and its directors in the Delaware Court of Chancery.
• The complaint asserted that Article V, Section 2 (three-year director terms) and Article VI, Section 1 (removal only for cause) of the Amended and Restated Certificate of Incorporation violated Delaware General Corporation Law.
• On February 24, 2026, a stipulation and proposed consent judgment was filed, and on March 11, 2026, the Court approved it, declaring the challenged provisions invalid and unenforceable.
• A Certificate of Correction was filed on March 11, 2026, reflecting these provisions as no longer part of the Certificate of Incorporation.
• As a result, directors' terms will expire at the 2026 annual meeting, and directors may be removed with or without cause by a majority vote.
• The action was dismissed with prejudice, but the Court retains jurisdiction for any mootness fee application.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; increased transparency and control over board elections due to corporate governance changes; continued risk of share price volatility due to early-stage pipeline and ongoing losses; potential for long-term value creation if product candidates succeed.
• Employees: Increased headcount and personnel-related costs, including termination benefits, indicate some organizational adjustments; continued focus on culture and competitive benefits.
• Customers (future): Potential for novel cancer therapies targeting significant unmet medical needs if product candidates are successfully developed and commercialized.
• Creditors: Continued reliance on equity financing and potential for debt financing in the future.
• Suppliers/Partners: Continued reliance on third-party manufacturers and collaborators for R&D and manufacturing, indicating ongoing business for these entities.

Next Steps

• Share Phase 1a interim data for the CTIM-76 trial in June 2026.
• Share Phase 1a interim data for the CT-95 trial in September 2026.
• Dose the first patient in the CT-202 Phase 1 trial in the third quarter of 2026.
• Continue to evaluate opportunities to expand the pipeline of selective cancer drug candidates and targets.
• Evaluate strategic opportunities to potentially accelerate development timelines and enhance commercial potential globally, including potential out-licensing.
• Seek additional capital through equity offerings, debt financings, collaborations, strategic transactions, and/or marketing, distribution, or licensing arrangements.
• Prepare for the 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

Context Therapeutics is making tangible progress in advancing its bispecific antibody pipeline, with three candidates now in or nearing Phase 1 clinical trials and interim data expected in 2026. This clinical momentum, coupled with a cash runway into mid-2027, provides some stability. However, the company's financial performance shows a worsening trend with increased net losses and cash burn, highlighting the substantial capital requirements and inherent risks of early-stage biopharmaceutical development. The resolution of the corporate governance lawsuit, while positive for shareholder rights, does not directly impact the core business operations or financial outlook. Given the high-risk, high-reward nature of clinical-stage biotech, the current financial trajectory, and the need for significant future funding, a 'hold' recommendation is appropriate. Investors should monitor upcoming clinical data and future financing activities closely for signs of de-risking or further financial strain.

Keywords

Context Therapeutics, CNTX, Biopharmaceutical, TCE bispecific antibodies, Solid tumors, CTIM-76, CLDN6, CT-95, MSLN, CT-202, Nectin-4, Phase 1 clinical trials, Oncology, Drug development, SEC filing, 10-K, Biologics, FDA approval, Clinical-stage, Corporate governance